Ovid Therapeutics Launches Pipeline Teach-In Webinar Series
June 04, 2020 08:00 ET
|
Ovid Therapeutics Inc.
Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE) NEW YORK, June 04, 2020 (GLOBE...
Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 12, 2020 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 08:00 ET
|
Ovid Therapeutics Inc.
Announced earlier today positive topline results from the Phase 2 ROCKET trial of OV101 for the treatment of Fragile X syndromePreviously reported encouraging initial results from Phase 2 ARCADE study...
Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome
May 07, 2020 07:30 ET
|
Ovid Therapeutics Inc.
OV101 met the study’s primary objective of safety and tolerabilityOV101 produced statistically significant reductions in behavioral and functional symptoms in individuals with Fragile X...
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome
March 30, 2020 08:00 ET
|
Ovid Therapeutics Inc.
Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have...
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020
March 11, 2020 08:00 ET
|
Ovid Therapeutics Inc.
Multiple clinical data readouts across Ovid’s pipeline expected in 2020Completed financings in the fourth quarter strengthening the balance sheet NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid...
Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting
March 05, 2020 16:05 ET
|
Ovid Therapeutics Inc.
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board
March 02, 2020 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
February 25, 2020 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
January 07, 2020 08:00 ET
|
Ovid Therapeutics Inc.
OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020Results From Phase 2 Signal-Finding ROCKET Trial and SKY...